15 September 2020

The RYR1 biobank is part of a study of the neuromuscular and multisystem features of patients with malignant hyperthermia or rhabdomyolysis related to RYR1 (ryanodine receptor type 1) variants. The main objective of the RYR1 biobank is to enable research into genetic causes and pathophysiological mechanisms, with identification of starting points for therapy. The biobank contains biomaterial (serum, heparin plasma, DNA, RNA and tissue) and clinical data from both children and adult patients.

  • Want to know more about these subjects? Click on the buttons below for more news.

    Radboud Biobank

Related news items


Control over Human Biomaterials Act [Wet zeggenschap lichaamsmateriaal] (Wzl)

19 July 2022

The Ministry of Health, Welfare and Sport (VWS) is currently preparing a Control over Human Biomaterials Act [Wet zeggenschap lichaamsmateriaal] (Wzl) which will serve in the future as a specific legal framework for the (further) use of body tissue for medical scientific research.

read more

Health-RI annual report

19 July 2022

Health-RI has presented the 2021 annual report. In this report they outline an overview of recent activities and results of the past year 2021 (in Dutch).

read more

SPIDI sub-biobank

19 July 2022

The SPIDI collection aims to assess the prognostic value of MRI-DWI (new form of MRI research) and biomarkers (brain-specific proteins in cerebrospinal fluid) in the first 24 hours after the occurrence of a spinal cord injury as a result of trauma.

read more

MyCoS sub-biobank

8 April 2022 The Radboud Biobank has added one new sub-biobank to the collection: MyCoS. read more